Novo Nordisk to begin supplying safety insulin needle to retail pharmacies
PRINCETON, N.J. Novo Nordisk is extending the availability of its safety insulin needle, NovoFine Autocover 30G from hospitals to retail pharmacies.
The needle has a plastic shield that helps reduce needle anxiety in patients and reduces the risk of accidental needle stick injuries by keeping the needle hidden before, during and after use and by using a red safety indicator that provides confirmation that the needle is locked.
It is designed and recommended for use with Novo Nordisk insulin delivery devices.
Valeant launches Bedoyecta supplement in the U.S.
ALISO VIEJO, Calif. Valeant Pharmaceuticals International today announced that it has launched Bedoyecta, the leading nutritional supplement in Mexico, in the United States through Hispanic independent grocers and major retailers serving ethnic communities.
Bedoyecta will be available in capsule and pediatric tablet form and will initially launch in Los Angeles and Houston in September 2007 with a national rollout by the end of the year.
“We are pleased to offer our Bedoyecta products to the Hispanic communities in the United States who have long known the brand in Mexico,” stated Wesley Wheeler, president, North America and research and development. “We are committed to providing the U.S. consumer with quality brands and it is important that we recognize the growth of the U.S. Hispanic population and the preferences of the Hispanic consumer.”
According to Valeant, approximately 40 percent of Hispanics in Mexico use vitamin supplements.
Valeant has assigned Houston-based Midway Importing as the distributor for Bedoyecta. Midway Importing currently services most Hispanic independent and chain grocers, pharmacy retail chains, and mass merchandisers that service the Hispanic market.
SCPI calls Natrol’s Promensil ads ‘dishonest’
WASHINGTON The nonprofit Center for Science in the Public Interest on Wednesday filed a claim to the Food and Drug Administration that the red-clover dietary supplement Promensil, distributed by Natrol, “is being deceptively marketed to women for the relief of hot flashes, night sweats, and mood swings,” the organization stated.
“Natrol’s ads for Promensil are some of the most dishonest we’ve seen for a dietary supplement in a while,” stated CSPI senior nutritionist David Schardt. CSPI conducted a detailed analysis of the scientific research on Promensil, the organization stated, and how it doesn’t support Natrol’s claims. CSPI’s letters to the FDA ask that Natrol reimburse deceived consumers, run corrective advertising to set the record straight, and pay a fine.
In response, Natrol today issued a press release outlining a published clinical treatment protocol that recommends supplementation with red clover isoflavones for women experiencing menopause symptoms.
According to the company, the protocol was developed by physicians and other healthcare professionals from the United States, United Kingdom, Canada, Australia and The Netherlands, and recommends supplementation with red clover isoflavones as a complementary therapy for treating mild-to-moderate menopause symptoms, as well as for treating severe symptoms when hormone replacement therapy is contraindicated.
“We have long had confidence in the significant body of clinical research indicating Promensil provides benefits for menopausal women by offering a unique isoflavone ratio that is a safe alternative to HRT,” stated Natrol vice president of research and development Michael Yatcilla. “Promensil can help relieve the frequency and severity of hot flashes, and promote breast and heart health, as well as emotional well-being.”